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The reactivation of Herpes Simplex virus (HSV) occurs in 70% to 80% of patients submitted
to autologous stem cell transplantation (ASCT); it increases the severity of chemotherapy-induced
mucositis. Therefore, the use of acyclovir in ASCT patients is considered standard practice.
However, the minimum dose needed to prevent reactivation is a matter of debate. We compared two
doses of acyclovir in a non-randomized fashion in 59 patients submitted to ASCT: 32 patients
received a dose of 125 mg/m2 IV every six hours and the subsequent 27 patients received a dose of
60 mg/m2 IV every six hours. Viral excretion was evaluated through weekly viral culture of oral
swabs. Grade 4 mucositis was more frequent in Group 1 (p= 0.03). The reactivation rates in
Groups 1 and 2 were 9% and 4%, respectively (p= 0.62, 95% confidence interval -7 – 18).
Prophylaxis with reduced doses of intravenous acyclovir seems to be as effective as a higher dose
in inhibiting HSV reactivation, with a significant reduction in cost. Prospective randomized
studies are needed to confirm our conclusions.
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Infection by Herpes Simplex virus (HSV) in patients
submitted to autologous hematopoietic stem cell
transplantation (ASCT) occurs in 70 to 80% of
seropositive individuals; it is due mostly to viral
reactivation [1]. Mucocutaneous lesions
indistinguishable from chemotherapy-induced mucositis
are the commonest clinical presentation, but other
manifestations may occur, including esophagitis,
pneumonia and disseminated infection [2]. The use of
acyclovir as prophylaxis against HSV reactivation is
considered standard in the care of ASCT patients during
the period of neutropenia [3]. However, since acyclovir
is costly, this drug accounts for a substantial proportion
of the total cost of antimicrobial agents. Therefore,
procedures to reduce the dose of acyclovir without
compromising its efficacy could have a significant and
favorable impact on the final cost of transplantation.
Randomized studies using different doses of
acyclovir in neutropenic patients have been performed
[2,4-7]. The rates of HSV reactivation varied between
0 and 20.8%, using doses ranging from 62.5 mg/m2
every four hours to 250 mg/m2 every eight hours. We
compared two doses of acyclovir as prophylaxis against
HSV disease in ASCT recipients in a non-randomized
fashion to determine if a lower dose (60 mg/m2 every
six hours) would be as effective as a higher dose (125
mg/m2 every six hours).
Materials and Methods
During a 36-month period (February 1997 to
February 2000), 59 consecutive patients were
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submitted to ASCT at the University Hospital,
Universidade Federal do Rio de Janeiro. Patients were
eligible to participate in the study if they had not received
acyclovir within 14 days of admission and if they signed
an informed consent. Prophylactic acyclovir was started
within five days of the initiation of the conditioning
regimen, and discontinued after neutrophil engraftment
(>500 neutrophils/mm3 for at least three consecutive
days) or after disappearance of any clinical sign of
mucositis. The subjects were studied consecutively and
allocated to one of the two arms in a non-randomized
fashion. The first 32 patients (Group 1) received
acyclovir at a dose of 125 mg/m2 intravenously every
six hours (February 1997 to January 1999) and the
following 27 patients (Group 2) received acyclovir at
a dose of 60 mg/m2 intravenously every six hours
(February 1999 to February 2000).
Evaluation of viral shedding was performed at
baseline and once a week, until neutrophil engraftment
or resolution of mucositis. Three sterile swabs were
rubbed in three distinct areas (right and left jugal
mucosa, and the mucosa below the lower incisors);
they were then transported in an appropriate viral
transport medium. The tubes were immediately sent to
the Virology Laboratory of the hospital and processed.
Viral isolation was performed according to standard
procedures [8]. Samples with cytopathic effect were
identified for HSV serotype by direct
immunofluorescence [9], using a monoclonal antibody
for each serotype. Patients who presented viral
reactivation during prophylaxis were considered to
have failed, and they received acyclovir at a dose of
250 mg/m2 every eight hours.
We evaluated the patients daily for the presence
and intensity of mucositis. The following data were
collected prospectively: age, gender, underlying disease
and its status at the time of ASCT, conditioning regimen,
history of previous infection by HSV (presence, time
elapsed from the first documentation of HSV, frequency
of relapses, previous use of antiviral drugs and time
elapsed since the last use of an antiviral agent).
Until 1998, empirical antibiotic therapy consisted
of ceftazidime plus amikacin; vancomycin was added
empirically to persistently febrile patients. From January
1998, cefepime was given as empirical therapy, and
vancomycin was given only in special situations [10].
Amphotericin B was started empirically after six days
of persistent fever, or whenever patients who had
become afebrile developed a new fever, provided that
no signs of bone marrow recovery were present.
Fever was defined as an axillary temperature >38oC
and neutropenia as a neutrophil count <500/mm3. Fever
during the period of neutropenia was classified
according to the Immunocompromised Host Society
criteria [11] as fever of unknown origin,
microbiologically documented, with or without
bacteremia, and clinically documented. The presence
of mucositis was not considered per se a documentation
of infection. HSV reactivation was defined as at least
one swab sample positive for HSV. Mucositis was
classified according to the World Health Organization
toxicity scale as follows: grade 0, no mucositis; grade
1 painless ulcer or erythema; grade 3, erythema, edema
and painful ulcers, but ability to eat, and grade 4, need
for parenteral or enteral support [12].
The analysis of data was performed on an intention-
to-treat basis and included all patients who were enrolled.
The outcome variable for the comparison between the
two groups was the HSV reactivation rate during acyclovir
prophylaxis. Assuming that the rate of HSV reactivation
in patients receiving acyclovir at a dose of 125 mg/m2
every six hours is approximately zero, we estimated a 30%
reactivation rate as the worst acceptable result with a
dose of 60 mg/m2 every six hours (we considered that
if a lower dose of acyclovir was not effective, the
reactivation rate would be similar to that reported in
the placebo arms of previously-published randomized
studies). With an alpha error of 5% and a beta error of
20%, 27 patients were needed in each group.
The Fisher’s exact test (two-tailed) or the Chi-square
test was used for the comparison between dichotomous
variables. Continuous variables were compared by the
Wilcoxon test. The 95% confidence interval (95% CI)
for the differences between proportions was also
calculated. P values ≤ 0.05 were considered statistically
significant. All analyses were performed using the Epi
Info 6-04b software (September 1997; CDC, Atlanta,
GA, USA).
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Results
Fifty-nine patients were included in the study. Thirty-
two received intravenous acyclovir 125 mg/m2 every
six hours (Group 1) and 27 received acyclovir at the
dose of 60 mg/m2 every six hours (Group 2). There
were no significant differences in age, gender, underlying
disease, conditioning regimen, source of stem cells and
previous history of HSV disease between the two
groups (Table 1), although there were slightly more
patients with Hodgkin’s disease in Group 2 (30% vs.
12%, 95% CI -3 – 38, p= 0.10), and more patients
with non-Hodgkin’s lymphoma in Group 1 (31% vs.
15%, 95% CI -4 – 37, p= 0.14). In addition, there
were nine patients in Group 1 with grade 4 mucositis
at baseline, compared to none in Group 2 (95% CI -1
– 19, p= 0.15). The use of antibacterial prophylaxis
was also more frequent in Group 1 (22% vs. 4%, 95%
CI 2 – 34, p= 0.059). All patients received fluconazole
as antifungal prophylaxis.
Thirty of the 32 patients in Group 1 (94%) and 26
of the 27 patients in Group 2 (96%) developed fever
(p= 1.0). Ceftazidime was the main beta-lactam
antibiotic used in Group 1 (15 patients, 50% of the
febrile episodes) and cefepime was used in 25 of the
26 febrile patients in Group 2 (p= 0.003). The
classification of the febrile episodes was not significantly
different between the two groups (Table 2). Likewise,
there were no significant differences in the median
duration of antibiotic therapy (10.5 [range 1 – 22] vs.
10 [range 4 – 25], p= 0.72, for Groups 1 and 2,
respectively), and success of the empirical antibiotic
therapy (47% in Group 1 and 41% in Group 2, 95%
CI -19 – 31, p= 0.74). Although the use of empirical
antifungal therapy was twice as frequent in Group 1
(31% vs. 15%, 95% CI -4 – 40), the difference was
not significant (p= 0.12).
Twenty-two patients of Group 1 (69%) and 17
patients of Group 2 (63%) presented mucositis (95%
CI -18 – 30, p=0.64). Grade 4 mucositis was observed
in six patients in Group 1 and in no patients in Group 2
(95% CI 5 – 32, p= 0.03). The median duration of
fever was somewhat longer in Group 1 than in Group
2 (5 days [range 1 – 11] vs. 3 days [range 1 – 13], p=
0.06). The duration of neutropenia was significantly
longer in Group 1 (11 days [range 8 – 26] vs. 8 days
[range 5 – 31], p<0.01).
Three patients (9%) in Group 1 and one patient
(4%) in Group 2 had reactivated HSV during the study
(95% CI -7 – 18, p= 0.62). The relative risk of HSV
reactivation in Group 2 was 0.40 (95% CI 0.04 –
3.58).
Three patients died during neutropenia: one in Group
1 and two in Group 2 (95% CI -16 – 7, p= 0.59).
None of these patients presented clinical signs of
disseminated HSV disease.
Acyclovir was given for a median of 17.5 days in
Group 1 and 15 days in Group 2 (p= 0.08). No patient
withdrew from the study and no adverse effects
attributable to acyclovir were observed.
Discussion
The strategy of defining the smallest effective dose
of acyclovir in the prophylaxis of HSV reactivation in
immunosuppressed patients has been tested since
1981, when Saral et al. [4] conducted a double-blind
randomized trial on 20 seropositive recipients of bone
marrow transplants using 250 mg/m2 IV every 8 hours;
the study by Angelopolus et al. [7] established that the
dose of 62.5 mg/m2 IV every four hours was as effective
as higher doses in patients with acute myeloid leukemia
in induction remission. We used smaller doses than
previously tested, and we did not observe an increase
in the reactivation rate.
The duration of neutropenia was longer in patients
in Group 1. This could be due to the fact that all patients
in Group 2 received peripheral blood stem cells,
whereas three patients in Group 1 received bone
marrow stem cells. ASCT with peripheral blood stem
cells is associated with a significant reduction in the
duration of neutropenia [13].
An intriguing observation of this study was the higher
proportion of patients with severe mucositis in Group
1. At baseline, there were three patients with grade 4
mucositis in Group 1 and none in Group 2. Since the
conditioning regimens were well balanced, it is not likely
Prophylaxis of Herpes Simplex
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Table 1. Characteristics of the groups of patients submitted to autologous stem cell transplantation
Characteristic Group 1 (n=32) Group 2 (n=27) 95% CI P
Age, median (range) 44.5  (8 – 63) 48 (11 – 65) 0.39
Gender Male:Female 15:17 14:13 -31 – 21 0.45
Underlying disease, n (%)
Hodgkin’s disease 4 (12) 8 (30) -38 – 3 0.10
Non Hodgkin’s lymphoma 10 (31) 4 (15) -4 – 37 0.14
Multiple myeloma 15 (47) 11 (34) -19 – 31 0.64
Others 3 (10) 4  (21) -22 – 11 0.69
Conditioning regimen, n (%)
CBV 14  (44) 11  (41) -22 – 28 0.82
Melphalan 200 mg/m2 15 (47) 11 (41) -19 – 31 0.64
Other 3  (9) 5  (18) -27 – 9 0.45
Source of Progenitor cells, n (%) -1 – 19 0.15
Bone marrow 3  (9) 0
Peripheral Stem cells 29 (91) 27  (100)
Time to start G-CSF, n (%) -37 – 12 0.23
Day +1 9 (28) 11  (41)
Day +5 23  (72) 16 (59)
Previous herpes labialis, n (%) 4 (12) 4 (15) -20 – 15 0.54
Mucositis on the first evaluation, n (%) 10 (31) 14  (52) -45 – 4 0.90
Mucositis Grade 4 on the first evaluation, 3 (9) 0  (0 ) -1 – 19 0.15
n (%)
Antibacterial prophylaxis, n (%) 7 (22) 1 (4) 2 – 34 0.059
95% CI = 95% confidence interval; CBV = cyclophosphamide, BCNU, etoposide; G-CSF = granulocyte colony-stimulating factor.
Table 2. Classification of the febrile episode in Groups 1 and 2
Group 1 n=32 (%) Group 2 n=27 (%) 95% CI P
Patients with fever 30 (94) 26 (96) -14 – 8
Fever of unknown origin 10 (33) 7 (27) -18 – 28 0.60
Bacteremia 11 (37) 10 (38) -27 – 22 0.89
Microbiologically documented 6 (20) 3 (11) -10 – 26 0.48
without bacteremia
Clinically documented 3 (10) 6 (23) -31 – 6 0.28
95% CI = 95% confidence interval.
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that this difference was due to different intensities of
chemotherapy. Although more patients in Group 1
presented HSV reactivation, the contribution of HSV
per se to the severity of mucositis is difficult to assess,
because of these baseline differences.
The duration of fever was slightly longer in Group
1; this could be due to the longer duration of neutropenia
or to the higher proportion of patients with severe
(grade 4) mucositis in this group. All patients who
presented HSV reactivation had prolonged fever. This
observation is in accordance with previous studies,
which showed that patients with HSV reactivation have
a more prolonged duration of fever during neutropenia
[14]. Acyclovir reduces the duration of fever and
prevents not only HSV reactivation but also Gram-
positive bacteremia [15]. This is not unexpected, since
HSV reactivation is associated with more severe
mucositis and mucositis and is a risk factor for Gram-
positive bacteremia in ASCT [16]. We did not observe
any difference in the rates of Gram-positive
bacteremias, but our study was not designed to
demonstrate such differences.
Our study has many limitations, the most important
being the non-randomized nature of allocation in the
two arms. Non-randomized studies are more prone to
result in significant imbalances that may considerably
reduce the strength of the conclusions. Indeed, in our
study, an unexpectedly higher proportion of patients in
Group 1 had grade 4 baseline mucositis, making it
difficult to interpret the results in terms of the prevention
of severe mucositis between the two arms. Another
limitation is that although the study had adequate power
to achieve the primary endpoint, it was not designed to
detect differences in the analysis of secondary events.
Despite these limitations, the results of our study
have some important practical implications. The
schedule of 125 mg/m2 every six hours consumes three
vials (250 mg) of acyclovir per day and the regimen of
60 mg/m2 every six hours requires 1.5 vials per day
(acyclovir is stable for 24 hours after reconstitution). If
we consider that both groups had the same duration of
acyclovir use (it was slightly lower in Group 2), a 50%
reduction in the total cost with acyclovir would be
achieved using the lower dose, without compromising
the effectiveness of HSV prophylaxis. Considering that
acyclovir accounts for almost 50% of the total cost of
antimicrobial agents in our institution (data not shown),
the cost reduction can be considerable.
In conclusion, acyclovir at a dose of 60 mg/m2 every
six hours seems to be as effective as a dose of 125 mg/
m2 every six hours in the prophylaxis of HSV
reactivation in ASCT recipients during neutropenia.
Prospective randomized studies will be needed to
confirm our results.
References
1. Saral R., Burns W.H., Prentice H.G. Herpes virus infections:
clinical manifestations and therapeutic strategies in
immunocompromised patients. Clin Haematol
1984;13:645-60.
2. Hann I.M., Prentice H.G., Blacklock H.A., et al. Acyclovir
prophylaxis against herpes virus infections in severely
immunocompromised patients: randomised double blind
trial. Br Med J (Clin Res Ed) 1983;287:384-8.
3. Guidelines for preventing opportunistic infections among
hematopoietic stem cell transplant recipients. Biol Blood
Marrow Transplant 2000;6:659-713.
4. Saral R., Burns W.H., Laskin O.L., et al. Acyclovir
prophylaxis of herpes-simplex-virus infections. N Engl
J Med 1981;305:63-7.
5. Gluckman E., Lotsberg J., Devergie A., et al. Prophylaxis
of herpes infections after bone-marrow transplantation
by oral acyclovir. Lancet 1983;2:706-8.
6. Wade J.C., Newton B., Flournoy N., Meyers J.D. Oral
acyclovir for prevention of herpes simplex virus
reactivation after marrow transplantation. Ann Intern
Med 1984;100:823-8.
7. Angelopulos C., Gore S., Braine H.G., et al. Successful
intravenous acyclovir (ACV) prophylaxis against Herpes
Simples Virus (HSV) infection/reativation during Intensive
chemotherapy of leukemia: 1000 courses (abstract H-143,
page 205). Abstracts of the 35th Interscience Conference
on Antimicrobial Agents and Chemotherapy, 1995.
8. Arvin A.M., Prober C.G. Herpes Simples viruses. In:
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken
RH, eds. Manual of Clinical Microbiology. Washington,
D.C.: American Society for Microbiology Press,
1995;876-83.
9. Zirn J.R., Tompkins S.D., Huie C., Shea C.R. Rapid detection
and distinction of cutaneous herpes virus infections
by direct immunofluorescence. J Am Acad Dermatol
1995;33:724-8.
Prophylaxis of Herpes Simplex
www.bjid.com.br
BJID 2005; 9 (August) 335
10. Nucci M., Landau M., Silveira F., et al. Application of the
IDSA guidelines for the use of antimicrobial agents in
neutropenic patients: impact on reducing the use of
glycopeptides. Infect Control Hosp Epidemiol
2001;22:651-3.
11. Hughes W.T., Armstrong D., Bodey G.P., et al. 1997
guidelines for the use of antimicrobial agents in
neutropenic patients with unexplained fever. Infectious
Diseases Society of America. Clin Infect Dis
1997;25:551-73.
12. Miller A.B., Hoogstraten B., Staquet M., Winkler A.
Reporting results of cancer treatment. Cancer
1981;47:207-14.
13. Beyer J., Schwella N., Zingsem J., et al. Hematopoietic
rescue after high-dose chemotherapy using autologous
peripheral-blood progenitor cells or bone marrow: a
randomized comparison. J Clin Oncol 1995;13:1328-35.
14. Baglin T.P., Gray J.J., Marcus R.E., Wreghitt T.G. Antibiotic
resistant fever associated with herpes simplex virus
infection in neutropenic patients with haematological
malignancy. J Clin Pathol 1989;42:1255-8.
15. Lonnqvist B., Palmblad J., Ljungman P., et al. Oral acyclovir
as prophylaxis for bacterial infections during induction
therapy for acute leukaemia in adults. The Leukemia
Group of Middle Sweden. Support Care Cancer
1993;1:139-44.
16. Cordonnier C., Buzyn A., Leverger G., et al. Epidemiology
and risk factors for Gram-positive coccal infections in
neutropenia: toward a more targeted antibiotic strategy.
Clin Infect Dis 2003;36:149-58.
Prophylaxis of Herpes Simplex
